Currently, several clinicopathological features and biomolecular markers, including tumor size (Goorts et al., 2017), histological grading (Alba et al., 2016), Ki67 (Alba et al., 2016), immunochemical (IHC)-based molecular typing (Haque et al., 2018) and stromal tumor-infiltrating lymphocytes (sTILs) are frequently used to predict pCR (Ali et al., 2017; Denkert et al., 2018). The gene discussed is MKI67; the disease is neoplasm.